Algeria vs United Kingdom: Average non-HDL cholesterol levels
Algeria
3.3
in 2018
United Kingdom
3.3
in 2018
Algeria rank
95th
United Kingdom rank
95th
Average non-HDL cholesterol levels over time
- Algeria
- United Kingdom
How they compare
Algeria currently reports 3.3 against 3.3 in United Kingdom, a difference of 0.
Across all 39 years both countries report, United Kingdom has been ahead every year.
Algeria ranks 95th and United Kingdom ranks 95th of 191 countries.
United Kingdom has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Algeria | United Kingdom | Difference | Ahead |
|---|---|---|---|---|
| 1980s | 3.42 | 4.48 | 1.06 | United Kingdom |
| 1990s | 3.63 | 4.25 | 0.62 | United Kingdom |
| 2000s | 3.59 | 3.89 | 0.3 | United Kingdom |
| 2010s | 3.41 | 3.48 | 0.0667 | United Kingdom |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average non-hdl cholesterol levels, Algeria or United Kingdom?
- Algeria, at 3.3 against 3.3 in United Kingdom as of 2018.
- What is the difference in average non-hdl cholesterol levels between Algeria and United Kingdom?
- 0, with Algeria ahead.
- How many years of comparable data are there for Algeria and United Kingdom?
- 39 years are reported by both, from 1980 to 2018.
- How do Algeria and United Kingdom rank globally for average non-hdl cholesterol levels?
- Algeria ranks 95th and United Kingdom ranks 95th of 191 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Average non-HDL cholesterol levels. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The estimated average level of non-high-density lipoprotein (non-HDL) cholesterol, commonly known as "bad cholesterol". Healthy levels are considered to be under 4mmol/L. Elevated levels of non-HDL cholesterol are a risk factor for chronic complications, including cardiovascular disease, and premature death.